TabletsClinical Overview
Sacubitril and Valsartan is a first-in-class Angiotensin Receptor-Neprilysin Inhibitor (ARNI) on the WHO Model List of Essential Medicines. Sacubitril is a prodrug whose active metabolite LBQ657 inhibits neprilysin (neutral endopeptidase), preventing the breakdown of endogenous natriuretic peptides (ANP, BNP, CNP) and promoting vasodilation, natriuresis, diuresis, and anti-remodeling, while valsartan selectively blocks the AT1 receptor, countering neprilysin-induced angiotensin II accumulation. Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure (NYHA II-IV and reduced ejection fraction).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally twice daily with water, with or without food. When switching from an ACE inhibitor, a mandatory 36-hour washout period is required before starting sacubitril/valsartan to avoid fatal angioedema. Follow cardiologist's uptitration schedule.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypotension, hyperkalemia, cough, dizziness, elevated serum creatinine. Rare/Severe: Boxed warning: Fetal toxicity in pregnancy; severe angioedema (life-threatening airway obstruction), and acute renal failure.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Fetal toxicity; contraindicated in pregnancy. Absolute contraindication with concurrent ACE inhibitors or within 36 hours of the last ACE inhibitor dose due to high risk of fatal angioedema. Contraindicated in history of angioedema. Regularly monitor serum potassium and renal function.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Valsartan Tablets 80 mg
Valsartan Tablets 80 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.
Sacubitril 49mg + Valsartan 51mg Tablets
Sacubitril and Valsartan is a first-in-class Angiotensin Receptor-Neprilysin Inhibitor (ARNI) on the WHO Model List of Essential Medicines. Sacubitril is a prodrug whose active metabolite LBQ657 inhibits neprilysin (neutral endopeptidase), preventing the breakdown of endogenous natriuretic peptides (ANP, BNP, CNP) and promoting vasodilation, natriuresis, diuresis, and anti-remodeling, while valsartan selectively blocks the AT1 receptor, countering neprilysin-induced angiotensin II accumulation. Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure (NYHA II-IV and reduced ejection fraction).
Valsartan Tablets 40 mg
Valsartan Tablets 40 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.
Sacubitril 97mg + Valsartan 103mg Tablets
Sacubitril and Valsartan is a first-in-class Angiotensin Receptor-Neprilysin Inhibitor (ARNI) on the WHO Model List of Essential Medicines. Sacubitril is a prodrug whose active metabolite LBQ657 inhibits neprilysin (neutral endopeptidase), preventing the breakdown of endogenous natriuretic peptides (ANP, BNP, CNP) and promoting vasodilation, natriuresis, diuresis, and anti-remodeling, while valsartan selectively blocks the AT1 receptor, countering neprilysin-induced angiotensin II accumulation. Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure (NYHA II-IV and reduced ejection fraction).